BioInvent CEO To Step Down And Seek Scientific Successor
Executive Summary
With its focus firmly on oncology, the Swedish biotech, and its outgoing chief, believe the company now needs someone with more scientific skills in the CEO role.
You may also be interested in...
BioInvent Stumbles In Busy Multiple Myeloma Space
The US FDA has halted the biotech company’s Phase II trial in multiple myeloma, a space that has seen a number of new drugs recently enter the market.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.